search
Back to results

The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section

Primary Purpose

Hypotension

Status
Unknown status
Phase
Phase 3
Locations
Greece
Study Type
Interventional
Intervention
Ondansetron 4mg
Ondansetron 8mg
100ml normal saline 0.9 percent
Sponsored by
Aretaieion University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hypotension focused on measuring ondansetron

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Physical status according to American Society of Anesthesiologists (ASA) I-II
  • Singleton pregnant women in full term pregnancy
  • Patients scheduled for cesarean section
  • Height 158cm-170cm

Exclusion Criteria:

  • patient's own refusal
  • contraindications to spinal anesthesia (coagulation disorders, inflammation at the puncture site, allergy to local anesthetics)
  • ondansetron allergy
  • body mass index> 33kg / m^2
  • height <158cm, or> 170cm
  • hypertensive disorders of pregnancy
  • cardiovascular disease
  • receiving selective serotonin reuptake inhibitors (SSRI's) or treatment for migraine
  • placenta previa.

Sites / Locations

  • Aretaieio Hospital, University of AthensRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Group A

Group B

Group C

Arm Description

Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.

Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.

Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.

Outcomes

Primary Outcome Measures

Change from Baseline Systolic Blood Pressure during cesarean section
every one minute after spinal anaesthesia and every five minutes after the delivery of the neonate until the end of the surgery
Change from Baseline Heart Rate
every one minute after spinal anaesthesia and every five minutes after the delivery of the neonate until the end of the surgery

Secondary Outcome Measures

Sensory blockade
Time for onset of sensory block at T4
Motor blockade
Time to Bromage 2 and to Bromage 3
Sensory regression
Time to two segment regression
Motor block regression
Time to Bromage 1 and Bromage 0
Time to maximum effect (Tmax)
Time when the motor blockade is complete and sensory blockade is in at the level of T4 dermatome
Time to minimum effect (Tmin)
Time to two segment regression of the sensory block (T6) and for motor block regression to Bromage1 and Bromage 0
Nausea
Scale for nausea (0:no nausea 10:worst possible nausea)
Vomiting
Number of vomits
Shivering
Yes:shiver No:no shiver
Total ephedrine consumption
Total ephedrine consumption intraoperatively
Total phenylephrine consumption
Total phenylephrine consumption intraoperatively
Total atropine consumption
Total atropine consumption intraoperatively
Neonate Apgar score
Apgar score in the 1st and 5th minute after delivery of the neonate
Umbilical cord ph
Umbilical cord ph after delivery
Need for administration of antiemetic agent
Need for administration of antiemetic agent intraoperatively

Full Information

First Posted
April 24, 2019
Last Updated
January 19, 2021
Sponsor
Aretaieion University Hospital
Collaborators
University of Athens
search

1. Study Identification

Unique Protocol Identification Number
NCT03931863
Brief Title
The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section
Official Title
The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Unknown status
Study Start Date
May 22, 2019 (Actual)
Primary Completion Date
May 2022 (Anticipated)
Study Completion Date
May 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aretaieion University Hospital
Collaborators
University of Athens

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The purpose of this study is to compare the administration of two different doses of ondansetron to placebo to prevent hypotension and bradycardia following spinal anaesthesia. Apart from haemodynamic parameters (blood pressure and heart rate),characters of the spinal blockage (time of onset and regression) will be recorded too.
Detailed Description
The day before surgery the procedure will be explained to the patient and the written consent will be obtained. In the operating room, intraoperative monitoring will include electrocardiography (ECG), noninvasive blood pressure, oxygen saturation by pulse oximetry (SpO2) and heart rate (HR). Two peripheral intravenous catheters wil be placed for fluid replacement and administration of drugs. Participants will be randomly assigned to one of the following groups: Group A: Women will receive 4 milligrams (mg) of ondansetron diluted in 100 milliliters (ml) of normal saline 0.9 percent 10 minutes before spinal anaesthesia Group B:Women will receive 8 mg of ondansetron diluted in 100ml of normal saline 0.9 percent 10 minutes before spinal anaesthesia Group C:Women will receive 100ml of normal saline 0.9 percent 10 minutes before spinal anaesthesia Subsequently, after receiving 500ml of colloid solution, spinal anesthesia will be performed at level L3-L4 or L4-L5 in the vertebral space with 1.6ml of 0.75 percent ropivacaine and 15mcg of fentanyl, using a 27-gauge pencil point spinal needle with patients in a left lateral position. After subarachnoid infusion, participants will be placed supine with left uterine displacement and anesthetic and motor blockage will be evaluated every one minute until anesthetic blockage reaches the level of T4 neurotome and the motor block becomes complete (Bromage grade 3). This time will be called Time to max effect (Tmax). Hypotension, defined as systolic blood pressure below 100 millimeters of Mercury (mmHg), will be treated using 5mg ephedrine if the heart rate is less than 100 beats per minute or with 20mcg of phenylephrine if the heart rate is greater than 100 beats per minute. Bradycardia, defined as a fall in heart rate below 60 beats per minute will be treated with atropine (0.6mg). Immediately after the delivery of the neonate, all women will receive a solution of oxytocin (20 units) intravenously. Half an hour before the end of the procedure they will receive an additional 1g of paracetamol and 75mg of diclofenac.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension
Keywords
ondansetron

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
All solutions will be prepared by an independent researcher who will not be further involved in the study eg data collecting or analyzing them. All solutions will look identical to the anesthetist who will administer them to the patients.Apart from the anesthetist, the surgery staff and the researchers recording the measurements will not know the therapeutic intervention team in which each patient has been randomized.
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Active Comparator
Arm Description
Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Arm Title
Group C
Arm Type
Placebo Comparator
Arm Description
Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Intervention Type
Drug
Intervention Name(s)
Ondansetron 4mg
Other Intervention Name(s)
Onda
Intervention Description
Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Intervention Type
Drug
Intervention Name(s)
Ondansetron 8mg
Other Intervention Name(s)
Onda
Intervention Description
Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Intervention Type
Drug
Intervention Name(s)
100ml normal saline 0.9 percent
Other Intervention Name(s)
N/S 0.9 percent
Intervention Description
Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Primary Outcome Measure Information:
Title
Change from Baseline Systolic Blood Pressure during cesarean section
Description
every one minute after spinal anaesthesia and every five minutes after the delivery of the neonate until the end of the surgery
Time Frame
60 minutes
Title
Change from Baseline Heart Rate
Description
every one minute after spinal anaesthesia and every five minutes after the delivery of the neonate until the end of the surgery
Time Frame
60 minutes
Secondary Outcome Measure Information:
Title
Sensory blockade
Description
Time for onset of sensory block at T4
Time Frame
20 minutes
Title
Motor blockade
Description
Time to Bromage 2 and to Bromage 3
Time Frame
20 minutes
Title
Sensory regression
Description
Time to two segment regression
Time Frame
120 minutes
Title
Motor block regression
Description
Time to Bromage 1 and Bromage 0
Time Frame
120 minutes
Title
Time to maximum effect (Tmax)
Description
Time when the motor blockade is complete and sensory blockade is in at the level of T4 dermatome
Time Frame
20 minutes
Title
Time to minimum effect (Tmin)
Description
Time to two segment regression of the sensory block (T6) and for motor block regression to Bromage1 and Bromage 0
Time Frame
120 minutes
Title
Nausea
Description
Scale for nausea (0:no nausea 10:worst possible nausea)
Time Frame
0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively
Title
Vomiting
Description
Number of vomits
Time Frame
0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively
Title
Shivering
Description
Yes:shiver No:no shiver
Time Frame
0 hours, 2 hours, 4 hours, 8 hours, 24 hours postoperatively
Title
Total ephedrine consumption
Description
Total ephedrine consumption intraoperatively
Time Frame
60 minutes
Title
Total phenylephrine consumption
Description
Total phenylephrine consumption intraoperatively
Time Frame
60 minutes
Title
Total atropine consumption
Description
Total atropine consumption intraoperatively
Time Frame
60 minutes
Title
Neonate Apgar score
Description
Apgar score in the 1st and 5th minute after delivery of the neonate
Time Frame
5 minutes
Title
Umbilical cord ph
Description
Umbilical cord ph after delivery
Time Frame
15 minutes
Title
Need for administration of antiemetic agent
Description
Need for administration of antiemetic agent intraoperatively
Time Frame
90 minutes

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Physical status according to American Society of Anesthesiologists (ASA) I-II Singleton pregnant women in full term pregnancy Patients scheduled for cesarean section Height 158cm-170cm Exclusion Criteria: patient's own refusal contraindications to spinal anesthesia (coagulation disorders, inflammation at the puncture site, allergy to local anesthetics) ondansetron allergy body mass index> 33kg / m^2 height <158cm, or> 170cm hypertensive disorders of pregnancy cardiovascular disease receiving selective serotonin reuptake inhibitors (SSRI's) or treatment for migraine placenta previa.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stavroula Karachanidi
Phone
+306970253686
Email
skarahanidi@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Anteia Paraskeva
Phone
+306972868078
Email
aparask@med.uoa.gr
Facility Information:
Facility Name
Aretaieio Hospital, University of Athens
City
Athens
State/Province
Attiki
ZIP/Postal Code
11528
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anteia Paraskeva, MD
Phone
+306972868078
Email
aparask@med.uoa.gr
First Name & Middle Initial & Last Name & Degree
Anteia Paraskeva, MD

12. IPD Sharing Statement

Learn more about this trial

The Effect of Ondansetron on Spinal Anesthesia in Caesarean Section

We'll reach out to this number within 24 hrs